Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Fineline Cube Jul 30, 2026
Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026
Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Policy / Regulatory

China’s CDE Tightens Drug Review Standards with New “No Supplemental Data” Rule for Major Deficiencies

Fineline Cube Jul 29, 2026
Company Drug

Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements

Fineline Cube Jul 30, 2026
Company Drug

Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression

Fineline Cube Jul 30, 2026
Company Drug

Haisco Pharmaceutical’s Crisugabalin Gains NMPA Approval for Post-Herpes Neuralgia Treatment

Fineline Cube Jul 8, 2024

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a leading pharmaceutical company based in China, has...

Company Drug

Hinova Pharmaceuticals’ HP537 Receives FDA Approval for Phase I/II Clinical Trial in Hematologic Malignancies

Fineline Cube Jul 8, 2024

Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech company based in Chengdu, has announced that it...

Company Drug

Easton Pharmaceutical Receives NMPA Approval for Generic Oxcarbazepine

Fineline Cube Jul 8, 2024

Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...

Company Drug

Amoytop Biotech’s Peginterferon α-2b Receives NMPA Approval for Primary Thrombocytosis Clinical Trial

Fineline Cube Jul 8, 2024

Amoytop Biotech Co. Ltd (SHA: 688278), based in Xiamen, has announced that it has received...

Company Drug

Daiichi Sanky’s Mirogabalin Gets Green Light from China for Diabetic Neuropathic Pain

Fineline Cube Jul 8, 2024

Daiichi Sanky (TYO: 4568), a pharmaceutical company based in Japan, has announced that it has...

Company Drug

Antengene’s Xpovio Secures NMPA Approval for R/R Diffuse Large B-Cell Lymphoma

Fineline Cube Jul 8, 2024

Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that it...

Company Drug

Sirnaomics’ STP122G Achieves Phase I Milestone with Positive Interim Data for Anticoagulation Treatment

Fineline Cube Jul 8, 2024

Sirnaomics Ltd (HKG: 2257) has announced the completion of the Phase I second sequence for...

Company Deals

Kindstar Global and MGI Tech Co., Ltd. Form Partnership to Establish Multi-Omics Service Center in China

Fineline Cube Jul 8, 2024

Kindstar Global (HKG: 9960), a biopharmaceutical company based in China, has announced a strategic partnership...

Company Legal / IP

Pharmaceutical Giants Face UK Industry Code Breach Allegations, Including Novartis and Pfizer

Fineline Cube Jul 8, 2024

Several multinational pharmaceutical corporations have been reprimanded for violating the UK’s Prescription Medicines Code, a...

Company Drug

Roche’s Tiragolumab Misses Primary Endpoints in NSCLC Trial, Study Halted

Fineline Cube Jul 8, 2024

Roche (SWX: ROG; SWX: RO; OTCMKTS: RHHBY), the Swiss pharmaceutical giant, has announced that a...

Company Drug

Medigene AG Secures Chinese Patent for TCR-T Therapy Targeting NY-ESO-1 and LAGE 1a

Fineline Cube Jul 8, 2024

Medigene AG (ETR: MDG1), a biopharmaceutical company based in Germany, has announced that it has...

Company

MicroPort Scientific Corp’s Subsidiaries Forecast Significant H1 2024 Revenue Growth

Fineline Cube Jul 5, 2024

MicroPort Scientific Corp (HKG: 0853), a leading medical device company, has seen its subsidiaries Shanghai...

Company Deals

Singlera Genomics Secures Over RMB 100 Million in Strategic Financing to Boost R&D and Commercialization

Fineline Cube Jul 5, 2024

Singlera Genomics Inc., a genetic testing and molecular diagnostics company with operations in San Diego,...

Company Drug

Doma Biopharmaceutical’s Bispecific ADC DM001 Receives FDA Clearance for Clinical Trial

Fineline Cube Jul 5, 2024

Doma Biopharmaceutical (Suzhou) Co., Ltd, a biopharmaceutical company based in China, has announced that it...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Green Light for HRS-9813 IPF Clinical Trial

Fineline Cube Jul 5, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Drug

Luye Pharma’s Oxycodone/Naloxone Product Receives NMPA Approval for Severe Pain Management

Fineline Cube Jul 5, 2024

Luye Pharma Group (HKG: 2186), a pharmaceutical company based in China, has announced that it...

Company Drug R&D

Semaglutide Use Linked to Rare Eye Condition NAION in New Study

Fineline Cube Jul 5, 2024

A recent study has identified a potential link between the use of GLP-1-targeted diabetes and...

Company Drug

J&J’s Rybrevant Earns First-Line NSCLC Approval in Canada, a Milestone for EGFR Exon 20 Patients

Fineline Cube Jul 5, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has announced that Rybrevant (amivantamab) has received its first...

Company Drug

Sanofi’s RSV Preventative Therapy Beyfortus Launches in China

Fineline Cube Jul 4, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has announced the commercial launch of Beyfortus...

Company Deals

Genertec and CTHG Fund Invest in Neusoft Medical Systems to Boost Medical Imaging

Fineline Cube Jul 4, 2024

China General Technology (Group) Holding Co Ltd, commonly referred to as Genertec, has announced plans...

Posts pagination

1 … 370 371 372 … 701

Recent updates

  • Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease
  • Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements
  • Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression
  • Huahai Pharmaceutical’s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares
  • CSPC Pharmaceutical’s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Company Drug

Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements

Company Drug

Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression

Company Drug

Huahai Pharmaceutical’s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.